Form 4: Amneal Pharmaceuticals Director Kevin Buchi Disposes of Shares Via Restricted Stock Unit Vesting
SEC Form 4 Filing
Director Kevin Buchi disposed of 76,453 shares of Amneal Pharmaceuticals Class A Common Stock on May 10, 2024, through the vesting of restricted stock units.
Summary
- On May 10, 2024, Kevin Buchi, a director of Amneal Pharmaceuticals, disposed of 76,453 shares of Class A Common Stock.
- This transaction occurred due to the vesting of restricted stock units (RSUs) that were granted on May 9, 2023.
- Each RSU represents a contingent right to receive one share of Amneal's Class A Common Stock.
- Following the transaction, Buchi directly owns 262,072 shares of Class A Common Stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing an insider transaction. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company directors.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership by a company director.
Key Dates
| Date | Description |
|---|---|
| 05/09/2023 | Reporting person was granted 76,453 restricted stock units. |
| 05/10/2024 | Date of transaction: disposal of shares through vesting of restricted stock units. |
| 05/10/2024 | Restricted stock units vested. |
| 05/14/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.